Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that diphlorethohydroxycarmalol significantly increased prostaglandin $E_2$ synthesis in HaCaT human keratinocytes by upregulating COX-1 and COX-2 expression, suggesting potential benefits from elevated $PGE_2$ production.

In this study, DPHC from the brown alga Ishige okamurae demonstrated potential to prevent androgenic alopecia by inhibiting hair loss and promoting hair growth through multiple cellular mechanisms.

Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.

This study found that hair regrowth occurred in 72.2% of alopecia areata patients treated with diphencyprone, with disease extent at baseline and duration affecting outcomes.

Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

This review reports that natural compounds show promise in slowing skin photoaging by targeting cellular pathways in keratinocytes and fibroblasts. However, comprehensive clinical studies are needed to verify their efficacy and safety.

Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.

This review explores the biology of wool follicles and suggests their potential use as research models in modern biology, but it reports no new findings.

In this study, alopecia areata patients treated with diphencyprone showed a significant increase in CD8 lymphocytes around hair bulbs, which may be associated with hair regrowth.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.

This study found that home-use diphenylcyclopropenone (H-DPCP) is a cost-effective alternative to office-use for severe alopecia areata, showing similar effectiveness with reduced costs.

This study found that increased Bcl-2 protein expression after DPCP treatment was associated with hair regrowth in alopecia areata patients, suggesting its role in inhibiting apoptosis.

This report describes two cases where patients developed vitiligo as a side effect of diphencyprone treatment for alopecia areata, highlighting the need to inform patients about this potential adverse effect.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.

This study found that human placenta hydrolysate effectively inhibited atopic dermatitis development in stimulated human cells and a mouse model, suggesting its potential as a therapeutic agent for related skin diseases.

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

This study found that the 15-PGDH inhibitor DPP improved endothelial function in hair-related cells exposed to DHT by reducing oxidative stress and enhancing angiogenic capacity.

This case report describes a 30-year-old Brazilian male who developed vitiligo lesions following diphencyprone therapy for alopecia areata.

This study explored the effects of DPP, a 15-PGDH inhibitor, on human follicle dermal papilla cells damaged by dihydrotestosterone and observed that DPP enhanced wound healing, reduced reactive oxygen species, and increased hair growth in ex vivo human hair follicle cultures.

This study found that forming inclusion complexes of DPCP with HPβCD using the 3D ground mixture method enhances its anti-inflammatory activity at lower doses compared to complexes with β-CD.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

This study reports that while DCP had similar treatment efficacy in propylene glycol and isopropanol for alopecia areata, the formulation in isopropanol was better tolerated.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

In this case report, a 9-year-old boy with diffuse alopecia areata showed improvement with topical diphencyprone immunotherapy, suggesting it as a safe and effective treatment option in pediatric cases of alopecia areata resistant to other therapies.

Researchers created a reliable method to measure dexpanthenol and resorcinol in hair products.

This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.

This study found that after 24 weeks of DPCP treatment for alopecia areata, there was a significant increase in new capillaries and hair regrowth detectable by videocapillaroscopy.

This study found that while DP concentrations in dust were higher in male dormitories, DP in hair was higher in females, suggesting differing metabolism between genders and that hair DP mainly originates internally.